Michael Tranfaglia, M.D.
Dr. Tranfaglia serves as Medical Director and Chief Scientific Officer of FRAXA. He coordinates the Foundation’s research strategy, working with academic and pharma scientists to develop new treatments for Fragile X and related developmental disorders. Dr. Tranfaglia has a B.A. from Harvard University and studied medicine at the University of North Carolina. After obtaining his M.D., he stayed at UNC for Psychiatry residency training, and then entered private practice in Newburyport, MA. He had specialized in the treatment of Anxiety Disorders before his son was diagnosed with Fragile X in 1992 and subsequent founding of FRAXA.